BIOMUNE SYSTEMS INC
NT 10-K, 1998-12-29
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: US AIRWAYS INC, 8-K, 1998-12-29
Next: INTERFACE SYSTEMS INC, 10-K, 1998-12-29



                            UNITED STATES
                 SECURITIES AND EXCHANGE COMMISSION
                        Washington, D.C.  20549

                              FORM 12b-25
                       NOTIFICATION OF LATE FILING

(Check one): X  Form 10-K __ Form 20-F  X Form 10-Q __ Form N-SAR

          For period ended: September 30, 1998

          [ ] Transition Report on Form 10-K and Form 10-KSB
          [ ] Transition Report on Form 20-F
          [ ] Transition Report on Form 11-K
          [ ] Transition Report on Form 10-Q and Form 10-QSB
          [ ] Transition Report on Form N-SAR
          For the transition period ended                                     
 

SEC File Number 0-11472 

CUSIP Number - 09061T 50 90

Nothing in this form shall be construed to imply that the Commission has
verified any
information contained herein.

If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification relates:______________________________

                      PART I-REGISTRANT INFORMATION

BIOMUNE SYSTEMS, INC.
- --------------------------------------
Full Name of Registrant

2401 South Foothill Dr.
Salt Lake City, Utah 84109
(801) 466-3441
- --------------------------------------
Address and telephone number of
principal executive office

                     PART II-RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the 
following should be completed.
(Check appropriate box)

[X]  (a)  The reasons described in reasonable detail in Part III of this form 
          could not be eliminated without unreasonable effort or expense;

[X]  (b)  The subject annual report, semi-annual report, transition report on
          Forms 10-K, 10-KSB, 20-F, 11-K, or Form N-SAR, or portion thereof will
          be filed on or before the 15th calendar day following the prescribed
          due date; or the subject quarterly report or transition report on Form
          10-Q, 10-QSB, or portion thereof will be filed on or before the fifth
          calendar day following the prescribed due date; and

[ ]  (c)  The accountant's statement or other exhibit required by Rule
          12b-25(c) has been attached if applicable.

                           PART III-NARRATIVE

     State below in reasonable detail the reasons why the Form 10-K, 10-KSB,
11-K, 20-F 10-Q, 10-QSB, N-SAR or the transition report portion thereof, could
not be filed within the prescribed time period.

     The annual report of the registrant on Form 10-K could not be filed
     because of delays encountered in finalizing the financial and other
     information needed to complete the report as it relates to the effects of
     a recent acquisition and revisions to the acquisition agreements, as well
     as recent personnel changes at the registrant.  

                        PART IV-OTHER INFORMATION

(1)  Name and telephone number of person to contact in regard to this 
notification.

Michael G. Acton, CEO         (801)            466-3441
       (Name)                 (Area Code)    (Telephone Number)

(2)  Have all other periodic reports required under Section 13 or 15(d) or the
     Securities Exchange Act of 1934 or Section 30 of the Investment Company
     Act of 1940 during the preceding 12 months (or for such shorter period that
     the registrant was required to file such report(s)) been filed?  If the
     answer is no,identify report(s).
                                                          X  Yes    __ No

(3)  Is it anticipated that any significant change in results of operations
     from the corresponding period for the last fiscal year will be reflected 
     by the earnings statements to be included in the subject report or portion
     thereof?

                                                       __ Yes       X  No

     If so:  attach an explanation of the anticipated change, both narratively
     and quantitatively, and, if appropriate, state the reasons why a
     reasonable estimate of the results cannot be made.



                          BIOMUNE SYSTEMS, INC.
              (Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned 
thereunto duly authorized.



Date   December 29, 1998           By:  /s/ Michael G. Acton
                                   --------------------------------- 
                              Michael G. Acton, Chief Financial Officer










© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission